- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:30 | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
| 05.06. | Duality Biologics: Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | 396 | PR Newswire | SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary... ► Artikel lesen | |
| 28.05. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 20, 2025 | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | 1 | HKEx | ||
| 23.05. | Duality Biotherapeutics: FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 79 | PR Newswire | Phase 1/2 first-in-human clinical study planned this year
SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606)... ► Artikel lesen | |
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.05. | Jefferies sets Duality Bio stock Buy rating, HK$500 PT | 3 | Investing.com | ||
| 12.05. | DUALITYBIO-B (09606): STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 1 | HKEx | ||
| 09.05. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 06.05. | DUALITYBIO-B (09606): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION | - | HKEx | ||
| 06.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.05.2025 | 426 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.05.2025
Aktien
1 KYG2929M1087 Duality Biotherapeutics... ► Artikel lesen | |
| 29.04. | DUALITYBIO-B (09606): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | DUALITYBIO-B (09606): EXEMPTION UNDER RULE 13.46(2) OF THE LISTING RULES REGARDING 2024 ANNUAL REPORT | - | HKEx | ||
| 24.04. | Chinese Biopharma Firms Chase Hong Kong IPO, After DualityBio's Sizzling Debut | 1 | Benzinga.com | ||
| 15.04. | Irrer Börsengang: BioNTech-Partner DualityBio explodiert am ersten Handelstag | 3.136 | Der Aktionär | Die Börse in Hongkong ist seit dem heutigen Mittwoch um ein Biotech-Unternehmen reicher. Duality Biotherapeutics (DualityBio) hat einen furiosen Start auf das Parkett gezaubert - nicht zuletzt dank... ► Artikel lesen | |
| 15.04. | BRIEF: Duality Biotherapeutics surges in Hong Kong trading debut | 2 | Bamboo Works | ||
| 15.04. | China's Duality Biotherapeutics surges over 200% in Hong Kong trading debut | 5 | Investing.com | ||
| 14.04. | DUALITYBIO-B (09606): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | 1 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,555 | +0,68 % | Biotech Report: Evotec und Qiagen leichter, US-Sektor verliert | (shareribs.com) Frankfurt / New York 17.06.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend nach unten. So korrigieren unter anderem Evotec und Qiagen. An der Wall Street rutscht der... ► Artikel lesen | |
| EVOTEC | 6,544 | -0,37 % | Nächste Übernahme und bahnbrechende Forschung - BioNTech, CureVac, Evotec, Vidac Pharma | Am Mittwoch konnten die Chefunterhändler von China und der USA bei ihren Verhandlungen in London Vollzug melden. Die dort getroffenen Vereinbarungen werden von den jeweiligen Staatschef Xi Jinping und... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,980 | +0,41 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 28,970 | -1,16 % | Wolfe Research initiates Avidity Biosciences stock with outperform rating | ||
| CARIS LIFE SCIENCES | 27,560 | -0,97 % | Caris Life Sciences Prices IPO Of About 23.53 Mln Shares At $21.00/shr | WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23.53 million shares of its common stock at a public offering price of $21.00... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,840 | -1,59 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 40,890 | -0,46 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 16,660 | -1,88 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| BIONTECH | 91,45 | +1,61 % | CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech | ||
| MODERNA | 22,215 | +1,53 % | Moderna erhält FDA-Zulassung für erweiterten RSV-Einsatz | Moderna hat für seinen RSV-Impfstoff mRESVIA die US-Zulassung auf Personen im Alter von 18 bis 59 Jahren mit erhöhtem Krankheitsrisiko ausgeweitet. Bislang war der Impfstoff in den USA nur für Menschen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,955 | -2,75 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 20,975 | +0,31 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 36,500 | -42,38 % | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | ||
| CUREVAC | 4,702 | -1,05 % | SONDERMELDUNG bei CureVac: Insider kaufen massenhaft Anteile - Dringend vor dem Wochenende handeln! | ||
| PRAXIS PRECISION MEDICINES | 42,505 | -1,06 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
Das Unternehmen DUALITY BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 26,200 Euro und damit -2,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.